EVCDX-BISPECIFIC-ANTIBODIE
Bispecific antibodies sweep into the clinic
Contract: 0x07bAA5f7325332E927311636470dEbDB65A30FCc
EVCDX-BISPECIFIC-ANTIBODIE is the tokenized index of the event card “Bispecific antibodies sweep into the clinic”. The card takes positions in its underlying assets — stocks, cryptos, options and perps — and the token's value moves with those positions. Bispecific antibodies bind two targets at once and are sweeping into the clinic. This card holds a real, price-weighted basket of seven listed developers, backed share-for-share in a brokerage account.
NAV Statistics
NAV per token
$5.50
Market price vs NAV
+2.96%
NAV updated
2026-08-08 03:12 UTC
Price-weighted level
5.50
Card index (base 100 at launch)
100.93
Holdings
| Asset | Symbol | Price | Weight |
|---|---|---|---|
| Xencor Xencor's XmAb platform engineers bispecific antibodies — core to the theme. |
XNCR | $20.00 | 52.65% |
| Immatics Immatics develops TCR-based bispecifics (TCER) targeting cancers. |
IMTX | $9.42 | 24.31% |
| Adagene Adagene builds masked, conditionally-activated antibodies including bispecific formats. |
ADAG | $4.14 | 10.12% |
| CytomX Therapeutics CytomX develops conditionally-activated Probody therapeutics including T-cell-engaging bispecifics. |
CTMX | $3.48 | 8.73% |
| Jasper Therapeutics Jasper Therapeutics develops antibody-based therapies in the same clinical space. |
JSPR | $0.65 | 1.71% |
| Context Therapeutics Context Therapeutics develops T-cell-engaging bispecifics for solid tumors. |
CNTX | $0.50 | 1.65% |
| GT Biopharma GT Biopharma builds tri-specific/bispecific NK-cell engager (TriKE) immunotherapies. |
GTBP | $0.30 | 0.83% |
1M Performance (trailing 30 days — the Card index measures since launch)
Aug 05
+1.17%
Aug 08